Do you want to read an article? Please log in or register.
Liquid biopsy: ready to guide therapy in advanced prostate cancer?
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Prostate.
Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS
doi: 10.1002/pros.24053.
SPECIAL REPORT
Gastrointestinal CancerFurther Publications
Why Liquid Biopsy for GI Tumor Treatment Matters
Genitourinary Cancer
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
J Urol.
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL
doi: 10.1016/j.juro.2016.12.022.
Genitourinary Cancer
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
N Engl J Med.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B, HERO Study Investigators
doi: 10.1056/NEJMoa2004325.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Ann Oncol.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B
doi: 10.1093/annonc/mdv257.
Genitourinary Cancer
Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer
J Urol.
Frye TP, George AK, Kilchevsky A, Maruf M, Siddiqui MM, Kongnyuy M, Muthigi A, Han H, Parnes HL, Merino M, Choyke PL, Turkbey B, Wood B, Pinto PA
doi: 10.1016/j.juro.2016.08.109.
RECOMMENDED
Genitourinary CancerRadio-Oncology
Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer
Strahlenther Onkol.
Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P, Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).
doi: 10.1007/s00066-019-01553-3.
Further Publications
Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients?
Ann Oncol.
Hofman P, Heeke S, Alix-Panabières C, Pantel K
doi: 10.1093/annonc/mdz196.
Genitourinary Cancer
Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study
Lancet Oncol.
Klemann N, Røder MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, Iversen P
doi: 10.1016/